FDA Issues Sales Ban on Vuse Solo Menthol E-Cigarette Products

Mar.18.2023
FDA Issues Sales Ban on Vuse Solo Menthol E-Cigarette Products
The FDA bans two Vuse Solo menthol e-cigarette products due to lack of evidence supporting their public health benefit.

On March 17th, the US Food and Drug Administration (FDA) issued a ban on the sale of two menthol-flavored e-cigarette products from the Vuse Solo brand owned by Reynolds American Inc. The ban is applicable to "Vuse Replacement Cartridge Menthol 4.8% G1" and "Vuse Replacement Cartridge Menthol 4.8% G2".


Currently, Renault is not allowed to sell these products in the United States or they will face enforcement action from the FDA. However, the company can resubmit an application to address the product defects involved in the MDO constraints.


The FDA has requested that applicants disclose whether mint-flavored e-cigarettes are more beneficial compared to tobacco-flavored e-cigarettes.


The FDA evaluates tobacco products for public health standards before they can be marketed through a Pre-Market Tobacco Application (PMTA). Upon reviewing the company's PMTA, the FDA determined that the application lacked sufficient evidence to prove that allowing the product to be sold would be in the best interest of public health, as required by the 2009 Family Smoking Prevention and Tobacco Control Act. Specifically, the evidence presented by the applicant did not demonstrate that mint-flavored e-cigarettes were less harmful to the adult smoking population compared to tobacco-flavored e-cigarettes.


Existing evidence, including data from the 2022 National Youth Tobacco Survey (NYTS), suggests that non-tobacco flavored e-cigarettes, including mint-flavored e-cigarettes, pose significant risks in terms of attraction, intake, and use among youths. In contrast, data indicates that tobacco-flavored e-cigarettes do not have the same appeal to young people and therefore do not pose the same risks. Given these existing differences in youth risks, the applicant needs to provide strong evidence to demonstrate that the use of their mint-flavored e-cigarette products can greatly reduce cigarette use among adult smokers compared to tobacco-flavored e-cigarettes.


According to data from The New York Times, Vuse is the second most popular brand among teenage e-cigarette users. The FDA aims to ensure not only that the manufacturers comply, but also that the distributors and retailers comply. Retailers who have any doubts about their inventory should contact Reynolds.


This is not the first action taken by the FDA.


This recent action is just one of many taken by the FDA to ensure that tobacco products sold in the United States undergo scientific review and receive PMTA approval. So far, the agency has received over 26 million PMTA applications and has made decisions on 99% of them. Currently, the FDA has approved 23 flavored electronic cigarettes for sale or distribution in the United States, which are the only ones allowed on the market legally.


The FDA has also rejected millions of non-compliant marketing applications, including 10 non-tobacco-flavored e-cigarette pods under the Vuse Solo brand. On January 24 of this year, the FDA also issued marketing bans (MODs) for two products by Reynolds American Inc., including the Vuse Vibe Tank Menthol 3.0% and Vuse Ciro Cartridge Menthol 1.5%.


In October 2022, the FDA issued an MDO (Modified Risk Order) for several mint-flavored e-cigarette products sold by Logic Technology Development. This was the first time the FDA had issued an MDO for products containing menthol after undergoing scientific review. However, a few days later, Logic received an order from the US Third Circuit Court of Appeals, which temporarily suspended the MDO's enforcement.


References:


The FDA has refused to allow two Vuse Solo menthol e-cigarette products to be marketed.


Related reading:


The FDA has announced that it has rendered decisions on 99% of the PMTA applications for electronic cigarettes, and intends to review the remaining popular products by the end of the year.


The FDA issues a marketing refusal order for two Vuse products.


Renault, a tobacco company owned by British American Tobacco, plans to appeal against the marketing ban imposed by the FDA.


The FDA has filed civil lawsuits and imposed fines against four electronic cigarette liquid manufacturers for the first time.


The FDA has scheduled a public hearing on April 12th to discuss the creation of new regulations for the manufacturing of tobacco products.


This document has been generated through artificial intelligence translation and is provided solely for the purposes of industry discourse and learning. Please note that the intellectual property rights of the content belong to the original media source or author. Owing to certain limitations in the translation process, there may be discrepancies between the translated text and the original content. We recommend referring to the original source for complete accuracy. In case of any inaccuracies, we invite you to reach out to us with corrections. If you believe any content has infringed upon your rights, please contact us immediately for its removal.

2Firsts “Decisive 2026” Concludes: Reviewing the 2025 U.S. Market and Mapping Compliance Pathways Ahead
2Firsts “Decisive 2026” Concludes: Reviewing the 2025 U.S. Market and Mapping Compliance Pathways Ahead
2Firsts hosted “Decisive 2026” in Shenzhen, bringing together industry perspectives to examine major shifts in the U.S. new tobacco market in 2025 and their global implications. Sessions covered U.S. market dynamics, technical insights from recently PMTA-authorized products, an investor lens on tobacco capital markets, and 2025 news/product highlights. The event underscored a structural shift from “gray business” toward compliance and sustainable growth, expected to become clearer by 2026.
Jan.09
U.S. FDA posts TPSAC meeting materials ahead of discussion on ZYN MRTP applications
U.S. FDA posts TPSAC meeting materials ahead of discussion on ZYN MRTP applications
On January 20, 2026, the U.S. Food and Drug Administration (FDA) posted meeting materials ahead of a virtual Tobacco Products Scientific Advisory Committee (TPSAC) meeting scheduled for January 22, 2026, to discuss modified risk tobacco product (MRTP) applications submitted by Swedish Match USA, Inc. for 20 ZYN nicotine pouch products.
Jan.21 by 2FIRSTS.ai
2Firsts Outlines 2026 Global Product Trends in the New Tobacco Industry
2Firsts Outlines 2026 Global Product Trends in the New Tobacco Industry
As regulation tightens and innovation matures, competition in the new tobacco industry is shifting. In its 2026 Global Product Trends in the New Tobacco Industry report, 2Firsts examines how heated tobacco, nicotine pouches, and vape products are moving beyond feature-driven upgrades toward system-level design, where experience management, compliance structure, and engineering capability increasingly shape long-term competition.
Jan.13 by 2Firsts Perspectives
Product | OXBAR Lists GOSLIM Disposable Vape on Its Website, Featuring Embedded Leather and a Slim Display Window Design
Product | OXBAR Lists GOSLIM Disposable Vape on Its Website, Featuring Embedded Leather and a Slim Display Window Design
OXBAR has updated its official website and listed a new disposable product, GOSLIM. The device is rated at 26,000 puffs, measures 40 × 22 × 110 mm, and weighs about 75 g, featuring an “embedded leather” exterior design. It supports two power modes—ECO and BOOST—and includes a digital display showing remaining battery percentage, remaining e-liquid level, and the active mode.
Jan.21 by 2FIRSTS.ai
Nicotine pouch brand SNÜ launches three fruit flavours, keeps “rub-and-smell” label to reduce retail shrink
Nicotine pouch brand SNÜ launches three fruit flavours, keeps “rub-and-smell” label to reduce retail shrink
UK nicotine pouch brand SNÜ has added three new flavours—Wild Cherry, Cherry Cola and Tropical Punch—spanning multiple nicotine strengths from 9mg to 60mg. The new products also retain the brand’s “rub-and-smell” packaging feature, designed to let shoppers preview the aroma without opening the can and help lower in-store product loss.
Feb.02 by 2FIRSTS.ai
U.S. Fifth Circuit judges question FDA’s claim it has no de facto ban on flavored refillable e-cigarettes
U.S. Fifth Circuit judges question FDA’s claim it has no de facto ban on flavored refillable e-cigarettes
Law360 reports that a Fifth Circuit panel expressed skepticism about the FDA’s claim that it has no de facto ban on flavored refillable e-cigarette products, noting that only six applications had been approved out of hundreds of thousands and that near-100% denials look like a ban.
Jan.07 by 2FIRSTS.ai